A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy
- 1 May 1992
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 28 (6-7) , 1018-1022
- https://doi.org/10.1016/0959-8049(92)90446-9
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- The concept of selectivity in 5-HT receptor researchEuropean Journal of Pharmacology: Molecular Pharmacology, 1990
- New antiemetic drugsCanadian Journal of Physiology and Pharmacology, 1990
- Antiemetic Efficacy of Escalating Doses of Alizapride against Chemotherapy-Induced EmesisOncology, 1989
- Activity of a new antiemetic agent: alizaprideCancer Chemotherapy and Pharmacology, 1988
- Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesisBritish Journal of Cancer, 1987
- The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: A prospective, randomized, double-blind trialClinical Pharmacology & Therapeutics, 1986
- Antiemetic Activity of Metoclopramide versus Alizapride during Cancer ChemotherapyTumori Journal, 1985